Évaluation du potentiel thérapeutique de COCO/CER2 pour le traitement de la dégénérescence maculaire liée à l'âge de type humide

 

Bruno Larrivée

CIUSSS de l'Est-de-l'Île-de-Montréal

 

Domaine : vieillissement

Programme Recherches sur la dégénérescence maculaire liée à l'âge (DMLA)

Concours 2019-2020

People currently suffering from wet age-related macular degeneration (AMD) are treated with injections of drugs called anti-VEGF, which prevent the development of blood vessels in the eye. Although these drugs have shown good results and may prevent the progression of AMD, some patients do not respond, and others may develop serious side effects. It is therefore imperative to develop new drugs to treat AMD. We have identified a protein called COCO, which prevents the development of blood vessels in the eye as well as anti-VEGF drugs. In addition, in preliminary tests, we have observed that COCO has no deleterious effects, unlike some anti-VEGF agents.

We therefore propose to study the clinical potential of COCO for the treatment of AMD. We hope to develop new drugs that can be used clinically.